Mri data suggest simufilam is not associated with amyloid-related imaging abnormalities (aria)

Austin, texas, oct. 25, 2023 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a clinical-stage biotechnology company, today announced a potentially significant safety finding based on interim magnetic resonance imaging (mri) brain data from alzheimer's patients who are enrolled in a phase 3 clinical trial of simufilam. the mri data suggest simufilam is not associated with treatment-emergent amyloid-related imaging abnormalities, or aria. mris were all analyzed for aria by board-certified neuroradiologists.
SAVA Ratings Summary
SAVA Quant Ranking